DEMADEX Drug Patent Profile

Which patents cover Demadex, and when can generic versions of Demadex launch?

Demadex is a drug marketed by Roche and Norvium Bioscience and is included in two NDAs.

The generic ingredient in DEMADEX is torsemide. There are sixteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the torsemide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Demadex

A generic version of DEMADEX was approved as torsemide by STRIDES PHARMA on May 27^th, 2003.

Summary for DEMADEX

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	126
Clinical Trials:	7
Patent Applications:	4,694
Drug Prices:	Drug price information for DEMADEX
What excipients (inactive ingredients) are in DEMADEX?	DEMADEX excipients list
DailyMed Link:	DEMADEX at DailyMed

See drug prices for DEMADEX

Recent Clinical Trials for DEMADEX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
New York City Health and Hospitals Corporation	Phase 4
Sarfez Pharmaceuticals, Inc.	Phase 1
Roxane Laboratories	N/A

See all DEMADEX clinical trials

US Patents and Regulatory Information for DEMADEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Roche	DEMADEX	torsemide	SOLUTION;INTRAVENOUS	020137-002	Aug 23, 1993		DISCN	Yes	No
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-002	Aug 23, 1993		DISCN	Yes	No
Roche	DEMADEX	torsemide	SOLUTION;INTRAVENOUS	020137-001	Aug 23, 1993		DISCN	Yes	No
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-001	Aug 23, 1993		DISCN	Yes	No
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-004	Aug 23, 1993		DISCN	Yes	No
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-003	Aug 23, 1993		DISCN	Yes	No

Expired US Patents for DEMADEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-002	Aug 23, 1993
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-003	Aug 23, 1993
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-003	Aug 23, 1993
Roche	DEMADEX	torsemide	SOLUTION;INTRAVENOUS	020137-002	Aug 23, 1993
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-001	Aug 23, 1993
Roche	DEMADEX	torsemide	SOLUTION;INTRAVENOUS	020137-002	Aug 23, 1993
Norvium Bioscience	DEMADEX	torsemide	TABLET;ORAL	020136-004	Aug 23, 1993

International Patents for DEMADEX

See the table below for patents covering DEMADEX around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1070313	DERIVES DE PYRIDINE (DERIVATIVES OF PYRIDINE)
Australia	7535587
Norway	863305
Finland	863305
Austria	53296
Finland	82189
Belgium	827844

DEMADEX Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for DEMADEX (Torsemide)

Market Overview

DEMADEX, also known as torsemide, is a loop diuretic used to treat conditions such as hypertension, heart failure, and edema. The market dynamics for DEMADEX are influenced by several key factors.

Increasing Prevalence of Chronic Diseases

The rise in chronic diseases such as hypertension, heart failure, and kidney diseases is a significant driver for the diuretic drugs market, including DEMADEX. According to the Transparency Market Research report, the increase in prevalence of chronic diseases like heart diseases, stroke, diabetes, hypertension, and cancer is projected to augment the diuretic drugs market value in the near future[1].

Demographic Factors

The aging population and the adoption of unhealthy lifestyles, including obesity, are also driving the demand for diuretic drugs. The aging population is more prone to chronic conditions that require diuretic treatment, thus contributing to the market growth[1].

Regional Market Performance

North America

North America constitutes a major share of the diuretic drugs market, including DEMADEX. This region is expected to maintain its dominance due to the high prevalence of chronic diseases. According to the Centers for Disease Control and Prevention, every six in 10 adults in North America suffer from chronic diseases, which are major causes of mortality and disability in the U.S.[1].

Asia Pacific

The Asia Pacific region is also experiencing rapid growth in the demand for diuretic drugs. The World Health Organization (WHO) reports that 41 million people die from noncommunicable diseases (NCDs) every year, accounting for 74.0% of all deaths worldwide. This rise in NCDs is fueling the demand for diuretic drugs in the region[1].

Financial Trajectory

Market Size and Growth

The global diuretic drugs market, which includes DEMADEX, is projected to grow at a CAGR of 5.5% from 2023 to 2031. The market size in the Asia Pacific region is expected to reach more than US$ 157.2 million by 2031[1].

Revenue and Sales

The retail pharmacies segment, which is a significant distribution channel for DEMADEX, accounted for the largest share in 2022 and is expected to lead the market in the near future. This is due to the increased availability of prescribed oral drugs in retail pharmacies[1].

Competitive Landscape

Major players in the diuretic drugs market, including those that manufacture DEMADEX, are AstraZeneca, Aurobindo Pharma, Bayer AG, Bristol-Myers Squibb Company, Cipla Ltd, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, GSK plc, Hikma Pharmaceuticals PLC, Mylan, Novartis Pharmaceuticals Corporation, Pfizer, Sanofi, and Teva Pharmaceutical Industries Ltd. These companies are introducing new medications and expanding their product portfolios to capture a larger market share[1].

Clinical and Therapeutic Use

Hypertension

DEMADEX has been shown to lower blood pressure effectively in patients with essential hypertension. In controlled studies, it demonstrated a significant reduction in systolic and diastolic blood pressures with minimal peak-trough difference and no significant orthostatic effect[2].

Heart Failure and Edema

DEMADEX is also used to treat congestive heart failure and edema. It increases the urinary excretion of sodium, chloride, and water, thereby reducing fluid overload and alleviating symptoms associated with these conditions[2].

Side Effects and Laboratory Changes

While DEMADEX is effective, it can cause several side effects, including hypokalemia, hypomagnesemia, and increases in blood urea nitrogen, creatinine, and uric acid levels. However, these changes are generally dose-related and reversible upon discontinuation of the drug[2].

Distribution and Accessibility

Distribution Channels

The global diuretic drugs market, including DEMADEX, is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Retail pharmacies dominate the market due to the widespread availability of prescribed oral drugs[1].

Future Outlook

Market Opportunities

The growing awareness about the benefits of diuretic drugs among patients with chronic disorders is expected to boost the market. Additionally, the increasing adoption of diuretic drugs in emerging economies presents lucrative opportunities for market players[1].

Challenges and Trends

Despite the growth opportunities, the market faces challenges such as the potential for side effects and the need for continuous monitoring of patients. However, advancements in pharmaceutical technology and the introduction of new formulations are expected to address these challenges and drive market growth[1][4].

Key Takeaways

• The diuretic drugs market, including DEMADEX, is driven by the increasing prevalence of chronic diseases and demographic factors such as an aging population.
• North America and the Asia Pacific region are key markets, with North America expected to maintain its dominance and the Asia Pacific region showing rapid growth.
• The retail pharmacies segment is the largest distribution channel for DEMADEX.
• Major pharmaceutical companies are actively involved in expanding their product portfolios and introducing new medications.
• DEMADEX is effective in treating hypertension, heart failure, and edema but requires careful monitoring due to potential side effects.

FAQs

What are the primary drivers of the DEMADEX market?

The primary drivers include the increasing prevalence of chronic diseases such as hypertension, heart failure, and kidney diseases, as well as demographic factors like an aging population and unhealthy lifestyles.

Which region dominates the DEMADEX market?

North America currently dominates the DEMADEX market due to the high prevalence of chronic diseases in the region.

What are the common side effects of DEMADEX?

Common side effects include hypokalemia, hypomagnesemia, and increases in blood urea nitrogen, creatinine, and uric acid levels.

How is DEMADEX typically distributed?

DEMADEX is primarily distributed through retail pharmacies, which account for the largest share of the market.

What is the projected growth rate of the diuretic drugs market?

The global diuretic drugs market, including DEMADEX, is projected to grow at a CAGR of 5.5% from 2023 to 2031.

Sources

1. Transparency Market Research: Diuretic Drugs Market | Industry Report, 2031
2. DailyMed: DEMADEX- torsemide tablet
3. Medexus Inc.: TSX: MDP | OTCQX: MEDXF - Market and Industry Data
4. Global Info Research: Global Torsemide Drug Market Size 2024-2031 by Recent Developments, Market Drivers, and Share Analysis